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Abstract: Stem cells have been long looked at as possible therapeutic vehicles for different health related problems. Among the different 
existing stem cell populations, Adipose derived Stem Cells (ASCs) have been gathering attention in the last 10 years. When compared to 
other stem cells populations and sources, ASCs can be easily isolated while providing higher yields upon the processing of adipose tissue. 
Similar to other stem cell populations, it was initially thought that the main potential of ASCs for regenerative medicine approaches was 
intimately related to their differentiation capability. Although this is true, there has been an increasing body of literature describing the 
trophic effects of ASCs on the protection, survival and differentiation of a variety of endogenous cells/tissues. Moreover, they have also 
shown to possess an immunomodulatory character. This effect is closely related to the ASCs’ secretome and the soluble factors found 
within it. Molecules such as hepatocyte growth factor (HGF), granulocyte and macrophage colony stimulating factors, interleukins (ILs) 
6, 7, 8 and 11, tumor necrosis factor- (TNF-), vascular endothelial growth factor (VEGF), brain derived neurotrophic factor (BDNF), 
nerve growth factor (NGF), adipokines and others have been identified within the ASCs’ secretome. Due to its importance regarding fu-
ture applications for the field of regenerative medicine, we aim, in the present review, to make a comprehensive analysis of the literature 
relating to the ASCs’ secretome and its relevance to the immune and central nervous system, vascularization and cardiac regeneration. 
The concluding section will highlight some of the major challenges that remain before ASCs can be used for future clinical applications.  
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1. INTRODUCTION 
Once considered to be a passive type of connective tissue stor-
ing excess energy as triglyceraldheydes, adipose tissue has now 
been established as an endocrine organ coupling (neuro)-endocrine 
and metabolic signaling [1]. Through the years there has been an 
increasing body of knowledge showing that the secretory products 
of this tissue regulate energy homeostasis, appetite/satiety, repro-
duction and insulin sensitivity. Simultaneously adipose tissue is 
also able to influence the neuroendocrine, endothelial, immunologi-
cal, hematological, angiogenic and vascular functions in an endo-
crine, paracrine and autocrine manner [1,2]. Adipose-derived Stem 
or Stromal Cells (ASCs) within adipose depots are responsible for 
the regeneration of the tissue over time by replacing the ~10% of 
mature adipocytes that turn over each year [3]. Similar to the broad 
function of the tissue from which they can be isolated, ASCs may 
have a larger spectrum of applications and functions than was ini-
tially thought. As with bone marrow-derived mesenchymal stem 
cells (BMSCs), the classical example of adult stem cell populations, 
it was believed that the major value of ASCs was mainly related to 
their differentiation capability towards different mature lineages. 
However recent evidence has shown that this paradigm may be 
somewhat limited. In recent years, it has been shown that the ASCs’ 
secretome, consisting of the proteins and growth factors secreted 
into the extracellular milieu, have a beneficial impact in different 
organs/systems within the human body. The objective of this re-
view is to provide a comprehensive analysis focused on the ASCs’ 
secretome, namely its constitution and most relevant factors,  
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and its actions on different organs and systems in different animal 
models. This review will start by giving a brief synopsis of ASCs’ 
basic biology followed by a section dedicated to their secretome, 
concluding with a summary of its potential impact in different 
models of injury and disease. 
2. SYNOPSIS OF ASCs BASIC BIOLOGY  
The existence of a population of multipotent stem cells within 
the adipose tissue arose after observations from pathological events 
within this tissue, such as progressive osseous heteroplasia and 
obesity [4,5]. The first is characterized by ectopic bone formation 
within the subcutaneous adipose layer of the skin [4,6-8]. Closer 
observations to these ectopic formations also revealed the presence 
of osteoblasts and chondrocytes, in addition to adipocytes [6], 
which were a clear indication of the presence of a multipotent stem 
cell population within the adipose tissue. In addition to this, obesity 
further reinforced this hypothesis [4,5]. In vivo models of adipo-
genesis suggest that the adipocyte is in fact a terminally differenti-
ated cell, with a limited capacity of proliferation and a turnover rate 
of around 6-15 months [9-11]. With this background, it was plausi-
ble to accept the existence of a population of adipose-derived stem 
cells that had pre-adipocyte function and were responsible for the 
replacement of terminal adipocytes throughout the life of an adult 
individual but were also capable of alternative lineage differentia-
tion [4].  
While Bjorntorp, Hauner, Van, and their colleagues first iso-
lated pre-adipocytes from rodent and human adipose depots over 
three decades ago [12-14] the nomenclature relating to ASCs and 
their isolation appeared for the first time almost ten years ago [15-
17]. Since then, ASCs have been reported to be found within the 
different white and brown adipose tissue depots (WAT or BAT) 
present in the body [18]. The simple surgical procedure, the easy 
and repeatable access to adipose tissue, and the uncomplicated-
based isolation procedures make this source quite attractive for both 
research and/or biomedical applications [1] when compared, for 
instance, to BMSCs. Current methods for its isolation are generally 
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based on enzymatic digestion of the adipose tissue followed by 
centrifugation to isolate the stromal/vascular fraction from primary 
adipocytes [5,19-21]. Upon isolation this stromal/vascular fraction 
will adhere to tissue culture plastic, while the hematopoietic frac-
tion and other contaminating cells can be depleted by different 
techniques.  
After in vitro expansion, ASCs acquire a fibroblast like mor-
phology, similar to the one observed for BMSCs [16], which are 
still considered as the gold standard within the field. Furthermore, 
ASCs also express a series of cell-specific proteins and CD markers 
phenotypically similar to BMSCs [19,22-24]. Further details on 
these topics can be found elsewhere [19,22-24] and are summarized 
in Table 1 regarding adhesion and receptor molecules, surface en-
zymes, extracellular matrix proteins and glycoproteins, skeletal 
proteins, complement regulatory proteins.  
Further research carried out by different groups also revealed 
the in vitro differentiation of these cells into osteogenic [16,22,25], 
chondrogenic [26,27], myogenic [28], neuronal-like [16,29,30], 
cardiomyocyte [31,32], epithelial [33,34] and endothelial lineages 
[35,36].  
3. ASCs SECRETOME – BASICS AND POSSIBLE APPLI-
CATIONS  
The secretome of ASCs has the potential to be a powerful tool 
in future approaches in developing cell/tissue based therapeutics for 
regenerative medicine. In fact, as it will be discussed later on and as 
shown in Table 2, there are numerous examples of the to beneficial 
effects that the ASC’s secretome exerts in the central nervous sys-
tems (CNS), immune system, heart, muscle and even in general cell 
survival. There has been an extensive literature [37-42] dealing 
with the secretory profile of pre-adipocytes, ASCs, or adipose tissue 
as determined by Enzyme Linked Immunoabsorbent Assay 
(ELISA) or related techniques. Nevertheless, the profile of the se-
cretory products of ASCs has only recently begun to be character-
ized at the mass spectrometry level. Although there are a number of 
papers dedicated to ASCs proteomic characterization [43-46] , most 
of them are actually focused on the proteome of cell lysates rather 
than the characterization of the secretome itself. A recent study 
characterized the ASCs secretome in the context of differentiation 
towards the adipogenic lineage [47]. The results were obtained after 
2D gel electrophoresis and tandem mass spectrometry of CM ob-
tained after 16 hours of culture from undifferentiated or day 9 adi-
pocyte differentiated P2 human ASCs. The latter allowed the identi-
fication of 101 individual proteins in the CM. Regarding the subcel-
lular location and functional categories of the secretome the follow-
ing results were reported: 
Subcellular Location 
The proteins in the CM displayed the following characteristics: 
41% had cytoplasmic associations, 15% were known secretory 
factors, 11% were nuclear derived, 4% were from the endoplas-
matic reticulum, 3% were attributed to the extracellular matrix 
(ECM), 4% were mitochondrial and 22% were not associated with a 
specific subcellular location. 
Function 
Regarding the function of the identified proteins 30% were re-
lated to cell metabolism, 7% were cytoskeletal, 8% were attributed 
to cell signaling, 7% to protein inhibitors, another 7% to protein 
degradation, 6% to protein processing, 3% were chaperones, 16% 
related to DNA repair, extracellular matrix, iron storage, GDP-
binding protein and mitosis, and 6% did not have an attributed 
function. 
This “contamination” with intracellular proteins could be due to 
leakage or, alternatively, to contamination related to cell death. In 
addition, other mechanisms such as exosome secretion cannot also 
be excluded. The presence of such cytosolic “contamination” is a 
potential artefact that can occur when working with either cell cul-
ture or tissue extract samples. Nevertheless, the fact that 29% of the 
101 identified proteins contained a predicted signal peptide consis-
Table 1. Surface Proteins Positively Identified in Adipose-Derived Adult Stem Cells [Adapted from 19 and 24] 
Protein Category Protein Name CD Number 
Adhesion molecules 
Tetraspan Protein 
Integrins b1 
Integrins a4 
Intercellular Adhesion Molecule 1 
Endoglin 
Vascular Cell Adhesion Molecule 
Activated Lymphocyte Cell Adhesion Molecule 
CD9 
CD29 
CD49d 
CD54 (ICAM-1) 
CD105 
CD106 (VCAM) 
CD166 (ALCAM) 
Receptor molecules 
Hyaluronate receptors 
Transferrin receptors 
CD44 
CD71 
Surface enzymes 
Endopeptidase (Common Acute Lymphoblastic Leukemia Antigen,) 
Aminopeptidase 
Ecto 5’ nucleotidase 
CD10 (CALLA) 
CD13 
CD73 
Extracellular matrix proteins 
and glycoproteins 
Collagen I 
Collagen III 
Osteopontin 
Osteonectin 
Thy-1 
MUC-18 
- 
- 
- 
- 
CD90 
CD146 
Skeletal proteins 
Intracellular alpha smooth muscle actin (subset of all cells) 
Vimentin 
- 
- 
Complement regulatory pro-
teins 
Decay Accelerating Factor 
Complement Protectin 
CD55 
CD59 
Histocompatibility A,B,C (Class I) - 
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tent with secretion via the endoplasmatic reticulum/golgi dependent 
pathway is of particular interest. Within these 29%, there were pre-
sent multiple adipokines such as adiponectin, angiotensin, cathepsin 
D, pentraxin, pregnancy zone protein and retinol binding protein. 
Moreover, leptin was also found, although in this case, only through 
antibody detection methods. Additionally molecules such as stro-
mal cell-derived growth factor (CXCL12) were also identified.  
Although the objectives of the second study were different, the 
paper by Kilroy et al. [48] provided complementary data on this 
topic. In this particular work the objective was to determine the 
cytokine profile of ASCs when exposed to different stimuli. Note-
worthy to mention is the fact that none of the factors addressed in 
the manuscript were described in the 2D electrophoresis and MS 
study performed by Zvonic et al. [47]. Although intriguing, these 
differences could be related to the structural properties of the pro-
tein factors, which may limit the sensitivity of their detection 
through MS based techniques [47]. This study revealed that ASCs 
secrete different cytokines, such as hepatocyte growth factor 
(HGF), granulocyte and macrophage colony stimulating factor 
(GM-CSF), interleukins (ILs) 6, 7, 8 and 11 and tumor necrosis 
factor- (TNF-). Moreover, it was also shown that their release 
profile can be modulated following exposure to different agents. 
For instance, ASCs exposed to basic fibroblast growth factor 
(bFGF) or epidermal growth factor (EGF) significantly increased 
their release of HGF, a cytokine with roles in both hematopoiesis 
[49] and vasculogenesis [50]. The HGF profile was further in-
creased when ascorbic acid was present. These results relating to 
HGF are consistent with those of Rehman et al. [41] and Nakagami 
et al. [42] regarding the ability of ASCs to secrete angiogenic cyto-
kines. In contrast, Kilroy et al. [48] also observed that ASCs could 
also respond to an inflammatory stimulus, such as lipopolysaccha-
ride (LPS). Under these conditions, the ASCs increased their secre-
tion of both hematopoietic (GM-CSF and IL-7) and pro-
inflammatory (ILs 6, 8, 11 and TNF-) cytokines. These results 
confirm that ASCs display a cytokine secretory profile similar to 
that of BMSCs. 
Both of these studies provided useful information on the ASCs 
secretome. However, other studies that do not specifically address 
release profile or the secretome, but rather the possible application 
of ASCs in regenerative medicine do also possess relevant content 
for this topic. Therefore, the following section will describe the 
relationship between these and other factors with the therapeutic 
potential of ASCs. 
4. MODULATION OF THE IMMUNE SYSTEM 
Cell based therapies, including ASCs, in combination with 
biomaterial and growth factor based approaches, play an important 
role on regenerative medicine strategies under development. It is 
therefore plausible to accept that once a few of these strategies are 
ready to be used in the current clinical practice there will be a de-
Table 2. Current Data on Adipose Tissue Derived Stem Cells Secretome 
References Topic of the Study Source Passage Samples Identification Technique Secreted Proteins 
Zvonic et al. [47] 
Secretome Characteriza-
tion 
Human 
Liposuction Aspi-
rates 
P1 
CM- collected after 
16 hours in Serum 
Free Medium 
2D Page, tandem mass 
spectrometry, Western blot 
Adiponectin, angio-
tensin, cathepsin D, 
pentraxin, pregnancy 
zone protein, retinol 
binding protein, 
CXCL12 
Kilroy et al. [48] 
Cytokine Profile; hema-
topoietic support 
Human 
Liposuction aspi-
rates 
P2 
CM - collected after 
72 hours under the 
stimulation EFG, 
FGF ascorbic acid or 
LPS 
ELISA, RT-PCR 
HGF, GM-CSF, ILs 
6,7,8,11, TNF- 
Cui et al. [53] Immunomodulation 
Human 
Liposuction Aspi-
rates 
P2 and P5 
Supernatants of 5 
days old co-cultures 
(transwell) between 
MLR and ASCs 
ELISA TGF-, HGF, PGE2 
Wang et al. [54] Inflammatory stimulus 
Cambrex Bio-
science P1 
CM – collected after 
24 hours of incuba-
tion with AScs 
ELISA VEGF, HGF, ILG-1 
Prichard et al.[55] 
Immunomodulation; 
biomaterials 
Rats – inguinal fat 
pad P2 
CM – collected after 
3 and 6 days over a 6 
day culturing period. 
ELISA IL-6, VEGF, TNF- 
Wei et al. [59] 
CNS regenerative medi-
cine 
Rat – subcutaneous 
adipose tissue P0 
CM – collected over 
a 24 hour period after 
confluence is reached 
ELISA BDNF, IGF-1 
McCkoy et al. 
[61] 
CNS regenerative medi-
cine Rat – fat pad P2 N/A 
Real Time PCR on in vitro 
expandaded ASCs BDNF, NGF, GDNF 
Sumi et al. [69] Vascularization 
Mice – inguinal 
adipose tissue 
P0 – freshly 
isolate Tissue Samples Immunocytochemistry VEGF 
Nakagami et 
al.[42] Vascularization 
Mice – inguinal 
adipose tissue Not referenced Cell extracts and CM Real Time PCR, ELISA 
HGF, VEGF, TGF-
2, FGF-2 
Rheman et al. [41] Vascularization 
Human - subcutane-
ous adipose tissue P0 -P2 
CM of ASCs cul-
tured under hypoxic 
conditions for 72 
hours 
Real Time PCR, ELISA 
VEGF, HGF, TGF-
, bFGF, GM-CSF 
Sadat et al. [77] Cardiac Regeneration 
Human – subcuta-
neous tissue Not referenced CM ELISA IGF-1, VEGF 
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mand for a reliable, safe and effective source of stem cells. Moreo-
ver, large numbers of cells will need to be obtained from these 
sources in order to facilitate a rapid application in the clinical thea-
tre. In this sense the use of allogeneic populations, in addition to 
autologous cells, would be a major advantage from both the patient 
and commercial standpoints. By employing allogeneic cells, master 
cell banks could be created, where stem cells would be available 
whenever needed. In fact ASCs have recently shown the potential 
not only to be used in either autologous or allogeneic cell trans-
plants, but simultaneously to act as modulators of the immune sys-
tem [51-57].  
For instance McIntosh and colleagues revealed that the fre-
quency of hematopoietic-associated markers and histocompatible 
locus antigen-DR [HLA-DR] tend to decrease with subsequent 
passages of human ASCs. Additionally in mixed lymphocyte reac-
tions (MLR), ASCs beyond P1 failed to elicit a response by MLR, 
suggesting the possible allogeneic potential of these cells. These in 
vitro results were then further confirmed by in vivo experiment in a 
spinal fusion model [52]. In this case results revealed that no T cell 
response was found and there was a low-titered, non-cytotoxic hu-
moral response to the allogenic implants.  
The work of Cui et al. [53] revealed some of the mechanisms 
associated to human ASCs mediated immunomodulatory effects. In 
this study it was shown that ASCs expressed HLA class I, but not 
class II molecules, which could only be induced upon ASCs incuba-
tion with interferon- (IFN). Similarly to what had already been 
described in other reports, passaged ASCs did not stimulate lym-
phocyte proliferation. Additionally it was also found that either 
IFN treated or non-treated ASCs could inhibit phytohemagglutinin 
(PHA)-stimulated lymphocyte proliferation. One of the striking 
findings in this manuscript was the evidence revealing that this 
immunosuppressive effect was not cell-to-cell contact dependent 
and therefore could be possibly attributed to soluble factors pro-
duced by ASCs. In order to determine if the suppressive effect was 
mediated by secreted cytokines, a cytokine profile was performed 
in conditioned media (CM) for the following molecules: Trans-
forming Growth Factor- (TGF-), HGF, prostaglandin E2 (PGE2) 
and IL-10. From these only the first three were detected in the CM 
through ELISA. Afterwards the level of each cytokine was meas-
ured in co-culture of ASCs with MLRs using a transwell culture 
system. Subsequent results revealed that of the three cytokines ini-
tially detected, only PGE2 levels were increased, suggesting that it 
might have a role in controlling the MLR proliferation. This hy-
pothesis was then confirmed by measurement of an increased MLR 
proliterative response when an inhibitor of PGE2, indomethacin, 
was present. This important study provides some hints regarding 
the molecular and growth factor cues that regulate the immuno-
modulatory character of ASCs. 
Wang et al. [54] also provided some important data regarding 
alterations of soluble factors produced by human ASCs following 
an inflammatory stimulus. In this case ASCs were incubated with 
TNF- for 24h, after which their supernatants were screened for 
vascular endothelial growth factor (VEGF), HGF and insulin like 
growth factor 1 (IGF-1). Results revealed that all three of these 
soluble factors were significantly increased in response to the in-
flammatory stimuli.  
Another interesting work is the one reported by Prichard et al. 
[55], which revealed that rat ASCs adhered to a polyurethane im-
plant modulate, and in part favoured, the foreign body response to 
the latter in a rat model. Quite interesting from the perspective of 
the present review the screenings made on the supernatants of 
ASCs when seeded in either polystyrene or polyurethane implants. 
According to the results that were presented, the ASCs secretion of 
IL-6, VEGF and TNF- could also be modulated by the surface 
upon which they were seeded. Thus, the bioscaffold/environment 
might be another mechanism to control the immunomodulatory 
character of ASCs. 
5. REGENERATIVE MEDICINE 
5.1. Central Nervous System 
As a result of the limited capacity of the CNS to self-repair, 
neurodegenerative disorders and CNS related injuries (such as 
Parkinson’s Disease (PD), Alzheimer’s Disease, Spinal Cord Inju-
ries and stroke/ischemia) have become one of the possible target 
applications for stem cell based therapies. The possible validity of 
ASCs for CNS regeneration purposes has been demonstrated in 
different models of injury and degeneration. These beneficial ac-
tions were initially attributed to the possible differentiation of ASCs 
towards the neuronal lineage. However, despite all the effort on this 
topic in recent years, there is no conclusive data yet on the in vivo 
differentiation of functional neurons from ASCs. Therefore, the 
strongest hypothesis to explain the role of ASCs in regeneration is 
mainly related to their possible trophic support provided through 
their secretome on the host cells [58,59].  
This hypothesis was initially tested using in vitro models. In or-
der to determine the role of ASCs’ soluble factors on neurospheres, 
Kang and colleagues [60] exposed the latter to human ASCs CM or, 
alternatively, co-cultured them using a cell culture transwell sys-
tem. These experiments revealed that the neuronal differentiation of 
the neurospheres in the presence of conditioned medium was com-
parable to contact-dependent co-cultures, and thus indicated a pos-
sible role for soluble, as opposed to cell surface, factors. However, 
no information regarding which factors could be involved was pro-
vided by the authors. Nevertheless this work served as a back-
ground for forthcoming papers dealing with this subject. The re-
ports of McCoy et al. [61] and Wei et al. [59] are good examples of 
this. 
In the first paper the goal was to study the role of non-
differentiated and differentiated ASCs on a rat model of PD. One 
week after the injury, differentiated and non-differentiated ASCs 
were injected in the substantia nigra. Neurochemical and behavioral 
analyses indicated that both populations abrogated dopaminergic 
neuronal cell death, which suggested that the pre-differentiation of 
ASCs towards the neuronal pathway did not determine the ability of 
ASCs to survive or protect the host populations in vivo. Moreover, 
immunohistological analysis failed to show robust differentiation of 
both cell transplants, a fact that further reinforces the view that the 
beneficial effects of ASCs in the CNS display trophic characteris-
tics. In addition to this, the authors also made an extensive gene 
expression analysis on possible soluble factors that could be impli-
cated in the observed phenomena. Quantitative real time PCR and 
semi-quantitative RT-PCR experiments detected high levels of 
Brain Derived Neurotrophic Factor (BDNF), Nerve Growth Factor 
(NGF) and Glial Derived Neurotrophic Factor (GDNF). The first 
two are well known growth factors involved in both the differentia-
tion of new neurons and the protection/survival of established dif-
ferentiated cells [62,63]. In contrast, GDNF is particularly involved 
in the specific survival and differentiation of dopaminergic neurons 
[64,65]. Moreover, the expression of the genes encoding these fac-
tors was potentiated whenever EFG/FGF-2 were present in the me-
dium. Although one must recall that this was a gene expression 
analysis, and not the quantification of the factor itself, the results 
presented in this report suggest that the ASC secretome will play a 
role in future CNS regenerative medicine studies. 
The paper by Wei and colleagues [59] further explores the CNS 
potential of the rat ASCs secretome. In this particular report only 
CM, rather than cells, were used. The objective was to study the 
neuroprotective effect of CM in a rat model of brain hypoxic-
ischaemic (HI) injury. Concentrated CM from cultured rat ASCs 
(ASC-CM) or control medium were infused through the jugular 
vein of neonatal Sprague-Dawley rats subjected to HI injury. The 
ASC-CM was administered either 1 hour before or 24 hours after 
induction of injury. Analysis at 1 week indicated that administration 
at both time points significantly protected against hippocampal and 
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cortical volume loss. Analysis of parallel groups for behavioral and 
learning changes at 2 months post-ischemia demonstrated that both 
treated groups performed significantly better than the controls in 
Morris water maze functional tests. Particularly interesting was the 
confirmation of penetration of the blood brain barrier by protein 
components of the injected CM, as well as their predominant bind-
ing to structures within affected regions of the brain. Additionally 
the authors attribute these findings to IGF-1 and BDNF. The first 
apparently provides protection against apoptosis, while the second 
can be involved, for instance, in the protection of glutamate excito-
toxicity. However, it should be said that these two factors do not 
necessarily account for all the observed phenomena, and thus a 
more in depth characterization on the neurotrophic factors present 
in the media is mandatory. Together, these publications demon-
strate that identified growth factors within the ASC secretome can 
positively modulate recovery and regeneration within the injured 
CNS.  
5.2. Vascularization 
Angiogenesis, which is the process that leads to the formation 
of new blood vessels, is a key event in any process of regenerative 
medicine. Through the years the concept of therapeutic angiogene-
sis to target problems such as tissue ischemia or to accelerate 
wound healing has emerged as one of them most promising thera-
pies to date [66]. Its concept is based on the stimulation of the pro-
liferation of collateral blood vessels that ultimately will lead to the 
re-vascularization of the affected area. Early clinical trials reported 
that the administration of angiogenic growth factors could enhance 
the formation of such vessels [67]. However the clinical efficacy of 
administering a single factor is still quite controversial [68,69]. As 
it happened with other areas of regenerative medicine ASCs and 
their secretome have been involved in a series of novel methodolo-
gies that are able to enhance angiogenesis in different conditions. 
Nearly simultaneously, pioneering studies by Planat-Bernard [34], 
Rehman [41], Miranville [70] and colleagues demonstrated that 
human ASCs displayed endothelial-like functionality in vitro and in 
vivo using hind limb ischemia models. 
More recently, Sumi and colleagues [69] reported the use of 
murine ASCs in an ischemic limb mouse model. The latter was 
achieved by resecting the right femoral and saphenous artery. ASCs 
were injected on the same day, using bone marrow MSCs, mature 
adipocytes and PBS as controls. Results revealed that ASCs signifi-
cantly augmented collateral blood vessel development that allowed 
the restoration of blood perfusion and capillary density in the 
ischemic model. These results were quite similar to those obtained 
for bone marrow MSCs, which are commonly viewed as the gold 
standard regarding mesenchymal like stem cells populations. Al-
though it was also observed that a small number of ASCs differen-
tiated into endothelial and smooth muscle cells, the authors attrib-
uted most of the success to the expression of VEGF, as assessed by 
immunocytochemistry. However, it may be short sighted to attrib-
ute the response solely to VEGF since ASCs do express a myriad of 
growth factors, some of which are endowed with angiogenic prop-
erties.  
Another study on this topic by Nakagami et al. [42] shed light 
on the possible mechanisms how soluble factors expressed by mur-
ine ASCs can induce angiogenesis. Their in vitro real time PCR 
studies showed that besides HGF, VEGF, TGF-2 and FGF-2, al-
ready mentioned in this manuscript, ASCs also expressed the genes 
for placental growth factor (PGF) and angiopoietins 1 and 2 (Ang-1 
and Ang-2). The expression of HGF and VEGF was then further 
confirmed by ELISA, with the concentration of HGF being higher 
than that of VEGF. Moreover the secretion of these two factors 
could be manipulated by adding different supplements to the culture 
system, a fact indicating that the action of ASCs in vivo could be 
determined by the local micro-environments. Finally their role on 
endothelial cells (ECs) viability and proliferation was assessed by 
treating ASCs CM with neutralizing antibodies for HGF and 
VEGF. With anti-HGF antibodies, there was a 25% inhibition on 
cell viability and a 48% inhibition on ECs migration, while anti-
VEGF antibodies led to an inhibition of around 23% on cell viabil-
ity and 26% on cell migration. Under these conditions it seems that 
although both factors have a similar role on maintaining cell viabil-
ity, HGF has a striking effect on ECs migration. Therefore HGF 
secreted by ASCs seems to display a crucial role in recruiting ECs 
in vivo for the formation of new blood vessels. 
The importance and role of HGF secreted by human ASCs on 
the angiogenesis of ischemic tissue was further demonstrated by 
Cai et al. [71]. In this work the expression of HGF was reduced to 
about 80% of the normal level by silencing HGF expression 
through RNA interference. In vitro experiments revealed that CM 
from these “HGF impaired” ASCs had a reduced ability to promote 
survival, proliferation and migration of both mature and progenitor 
endothelial cells. Moreover it was also observed that when com-
pared to control populations of ASCs, the HGF silenced cell popu-
lations had also a reduced ability for promoting reperfusion in a 
mouse ischemic hind-limb model. Additionally it was also seen that 
in these cases there were smaller densities of capillaries and fewer 
ASCs in the ischemic limb.  
Another interesting report regarding the beneficial effects of the 
soluble factors secreted by human ASCs was put forward by Reh-
man et al. [41]. In this work it was shown that when cultured in 
hypoxic conditions ASCs were able to increase their VEGF secre-
tion by 5 fold. Moreover, CM obtained from ASCs grown under 
hypoxic condition were able to increase the growth of endothelial 
cells and simultaneously to reduce the apoptosis rate of this popula-
tion of cells. These experiments were a clear indicator of the role of 
the surrounding environment on ASCs secretome. Moreover, the 
way that these cells reacted to hypoxic conditions is a further indi-
cator on their possible role in clinical conditions that involve 
ischemia.  
Overall these reports clearly show the importance of the secre-
tome, namely HGF and VEGF, of ASCs in inducing angiogenesis 
in areas that have undergone ischemic episodes. However, it is not 
only in ischemic tissues that vascularization is important. In proc-
esses such as wound healing the formation of new blood vessels is 
also extremely important, and ASCs have potential utility in such 
models. Kim et al. [72] have shown the role of different cytokines 
in controlling fibroblast proliferation/migration, which could obvi-
ously affect the time required for wounds to heal. Moreover, they 
have [73] also shown that ASCs could protect fibroblasts from oxi-
dative stress. Although the authors did not attribute these results to 
a specific factor, the paper refers to a proteomic based analysis of 
ASCs CM that reveal the presence of different soluble factors that 
might be involved in this process. Given this, Blanton and col-
leagues [74] used a porcine full-thickness wound model to evaluate 
the therapeutic usage of ASCs for these purposes. Results revealed 
that although there were no differences in re-epithelization, the 
groups treated with ASCs had higher densities of microvessels. 
Simultaneously the ASCs were found near the new vasculature and 
the VEGF levels were higher in the groups using ASCs, thus sup-
porting the importance of these cells in regulating wound repair.  
5.3. Cardiac Regeneration 
Cardiac regeneration has been another area where ASCs have 
been applied and the effects of their secretome have been observed. 
In fact, there have been a number of papers reporting positive ef-
fects of these cells when transplanted/injected in different animal 
models of myocardial infarction/failure [75,76]. Similar to other 
ASC applications in ischemic models, the improvement on the car-
diac regeneration in these animal models was attributed to an in-
crease in vascularization and/or a cell protective effect, namely by 
reducing apoptosis. Although the information is limited, Sadat and 
colleagues [77] identified the contribution of VEGF and IGF-1 to 
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this phenomenon in co-culture studies using human ASCs. Through 
RNA silencing experiments it was possible to conclude that 62.5% 
of this anti-apoptotic effect was mediated by IGF, while, as ex-
pected, VEGF was mainly involved in the promotion of angiogene-
sis. Thus, the angiogenic and anti-apoptotic actions of the ASC 
secretome contribute to tissue repair in multiple depots by prevent-
ing post-ischemic damage. In addition to the growth factors men-
tioned, it is likely that other ASC derived proteins contribute to this 
favourable outcome; however, additional studies will be necessary 
to validate this speculation. 
CONCLUSIONS 
Multiple studies demonstrate that ASCs secrete several soluble 
factors with effects on different cell populations. At the immune 
system level there is substantial evidence that PGE2 partially regu-
lates some of the immunomodulatory properties/effects of ASCs. 
Moreover, ASCs also respond to inflammatory stimuli from their 
environment by increasing their expression of angiogenic factors 
such as VEGF, HGF and IGF-1 as well as hema-
topoietic/inflammatory factors such as G-CSF, M-CSF, IL-6 and 
TNF-. Regarding the CNS, the factors implicated are different and 
it is currently known that BDNF, GDNF, NGF and IGF secreted by 
ASCs have different roles on neuroprotection and differentiation. 
Finally there is evidence suggesting that IFG-1 secreted by ASCs 
may protect cardiomyocytes from apoptotic cell death. Overall, it is 
evident that many ASC secreted factors act through mechanisms 
that mediate protection against cell death or, alternatively, induce 
cell migration and proliferation. Alternatively they can indirectly 
act on the targeted cell populations. For instance by promoting vas-
cularization, they can be indirectly linked to an increase of oxygen 
and nutrients in the affected areas, which may than promote local 
regenerative processes. Although this information is quite useful, 
given the plethora of factors that are expressed by ASCs, it is ex-
pected that other factors might affect, in different forms, fully dif-
ferentiated and progenitor cells at the target tissues. It will be then 
necessary to employ more powerful techniques. Up to now, most of 
the reports have focused on the same factors. While this is useful as 
it allows us to understand the different function of this small set of 
growth factors, it limits discovery approaches towards the secre-
tome as a therapeutic tool. Therefore the application of unbiased, 
global discovery techniques such as liquid chromatography/MS 
need to be applied and the resulting data correlated with that ob-
tained by complementary approaches such as, for instance, ELISA 
or luminex based assays. By doing so, a better understanding of the 
secretome will be attained, with the possibility of discovering new 
potential factors. In addition to this information it is advisable that 
serial studies be made on how the secretome changes according to 
the passage of cells, as the latter will be most likely different from 
passage to passage. Additionally other questions can also be posed. 
For instance it remains unclear if it is preferable to transplant ASCs 
or, alternatively, their CM; both approaches may have a therapeutic 
potential best suited to a particular pathology dependent on the 
target disease/injury. If a prolonged release of factors is needed, 
then ASCs transplant may be beneficial. The use of genetically or 
culture condition modified ASCs capable of releasing induced lev-
els of a particular cytokine or growth factor merits consideration. 
Alternatively, if an initial burst of factors is desired, than the injec-
tion of concentrated CM from ASCs would be the most logical 
approach. Another relevant topic is how the secretome of ASCs can 
be modulated. A possible hypothesis could be through the use of 
bioreactors, as ASCs are sensitive to dynamic environments. An-
other possibility would be the use of defined media that specifically 
trigger the expression of the desired trophic factors. Alternatively 
the growth of these cells in suspension based bioreactor systems 
and in contact with engineered biomaterials surfaces, could also be 
possible routes to follow. With these approaches, it will probably be 
possible to expand the applications of ASCs, and their secretome, to 
a wider range of regenerative medicine protocols in a rational, evi-
dence-based manner.  
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